Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI
The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression. In this study, we investigated the predictive value of PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET PET) durin...
Gespeichert in:
| Veröffentlicht in: | Journal of Nuclear Medicine 2012-07, Vol.53 (7), p.1048-1057 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1057 |
|---|---|
| container_issue | 7 |
| container_start_page | 1048 |
| container_title | Journal of Nuclear Medicine |
| container_volume | 53 |
| creator | Galldiks, Norbert Langen, Karl-Josef Holy, Richard Pinkawa, Michael Stoffels, Gabriele Nolte, Kay W Kaiser, Hans J Filss, Christan P Fink, Gereon R Coenen, Heinz H Eble, Michael J Piroth, Marc D |
| description | The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression. In this study, we investigated the predictive value of PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET PET) during treatment.
In a prospective study, 25 patients with glioblastoma were investigated by MRI and (18)F-FET PET after surgery (MRI-/FET-1), early (7-10 d) after completion of radiochemotherapy with temozolomide (RCX) (MRI-/FET-2), and 6-8 wk later (MRI-/FET-3). Maximum and mean tumor-to-brain ratios (TBR(max) and TBR(mean), respectively) were determined by region-of-interest analyses. Furthermore, gadolinium contrast-enhancement volumes on MRI (Gd-volume) and tumor volumes in (18)F-FET PET images with a tumor-to-brain ratio greater than 1.6 (T(vol 1.6)) were calculated using threshold-based volume-of-interest analyses. The patients were grouped into responders and nonresponders according to the changes of these parameters at different cutoffs, and the influence on progression-free survival and overall survival was tested using univariate and multivariate survival analyses and by receiver-operating-characteristic analyses.
Early after completion of RCX, a decrease of both TBR(max) and TBR(mean) was a highly significant and independent statistical predictor for progression-free survival and overall survival. Receiver-operating-characteristic analysis showed that a decrease of the TBR(max) between FET-1 and FET-2 of more than 20% predicted favorable survival [corrected], with a sensitivity of 83% and a specificity of 67% (area under the curve, 0.75). Six to eight weeks later, the predictive value of TBR(max) and TBR(mean) was less significant, but an association between a decrease of T(vol 1.6) and PFS was noted. In contrast, Gd-volume changes had no significant predictive value for survival.
In contrast to Gd-volumes on MRI, changes in (18)F-FET PET may be a valuable parameter to assess treatment response in glioblastoma and to predict survival time. |
| doi_str_mv | 10.2967/jnumed.111.098590 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1023292663</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2722873091</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-38c9e8fcac5914b5cfd45170778d56e3f0549d3456c53e19160b9352465ee0543</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhkVpaDbb_oBeiqCX5KCtPixZOoaQpIEtCSU9G612nHixLVcjU_bS315tNrn0JEbzzIs0DyGfBV9JZ-pvu3EeYLsSQqy4s9rxd2QhtNJMG1O_JwsujGBac31KzhB3nHNjrf1ATqU0lZbOLsjfS0RAHGDMNLY0J_D5pUiAUxwRaDfSyeeu3CH90-Vn-tR3cdN7zHHwdMZufKL37FwyYW9Y288xRcjP-_6CrVnep1gAoA_Xj4egEIfJpw7jSHOkP37efSQnre8RPr2eS_Lr5vrx6jtb39_eXV2uWVC1zEzZ4MC2wQftRLXRod1WWtS8ru1WG1At15XbqkqboBUIJwzfOKVlZTRA6aklOT_mTin-ngFzM3QYoO_9CHHGRnCppJPGqIJ-_Q_dxTmN5XUHypXYuux4ScSRCuWHmKBtptQNPu0L1BzkNEc5TZHTHOWUmS-vyfPm0HqbeLOh_gHASIs0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1029935715</pqid></control><display><type>article</type><title>Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Galldiks, Norbert ; Langen, Karl-Josef ; Holy, Richard ; Pinkawa, Michael ; Stoffels, Gabriele ; Nolte, Kay W ; Kaiser, Hans J ; Filss, Christan P ; Fink, Gereon R ; Coenen, Heinz H ; Eble, Michael J ; Piroth, Marc D</creator><creatorcontrib>Galldiks, Norbert ; Langen, Karl-Josef ; Holy, Richard ; Pinkawa, Michael ; Stoffels, Gabriele ; Nolte, Kay W ; Kaiser, Hans J ; Filss, Christan P ; Fink, Gereon R ; Coenen, Heinz H ; Eble, Michael J ; Piroth, Marc D</creatorcontrib><description>The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression. In this study, we investigated the predictive value of PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET PET) during treatment.
In a prospective study, 25 patients with glioblastoma were investigated by MRI and (18)F-FET PET after surgery (MRI-/FET-1), early (7-10 d) after completion of radiochemotherapy with temozolomide (RCX) (MRI-/FET-2), and 6-8 wk later (MRI-/FET-3). Maximum and mean tumor-to-brain ratios (TBR(max) and TBR(mean), respectively) were determined by region-of-interest analyses. Furthermore, gadolinium contrast-enhancement volumes on MRI (Gd-volume) and tumor volumes in (18)F-FET PET images with a tumor-to-brain ratio greater than 1.6 (T(vol 1.6)) were calculated using threshold-based volume-of-interest analyses. The patients were grouped into responders and nonresponders according to the changes of these parameters at different cutoffs, and the influence on progression-free survival and overall survival was tested using univariate and multivariate survival analyses and by receiver-operating-characteristic analyses.
Early after completion of RCX, a decrease of both TBR(max) and TBR(mean) was a highly significant and independent statistical predictor for progression-free survival and overall survival. Receiver-operating-characteristic analysis showed that a decrease of the TBR(max) between FET-1 and FET-2 of more than 20% predicted favorable survival [corrected], with a sensitivity of 83% and a specificity of 67% (area under the curve, 0.75). Six to eight weeks later, the predictive value of TBR(max) and TBR(mean) was less significant, but an association between a decrease of T(vol 1.6) and PFS was noted. In contrast, Gd-volume changes had no significant predictive value for survival.
In contrast to Gd-volumes on MRI, changes in (18)F-FET PET may be a valuable parameter to assess treatment response in glioblastoma and to predict survival time.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.111.098590</identifier><identifier>PMID: 22645298</identifier><identifier>CODEN: JNMEAQ</identifier><language>eng</language><publisher>United States: Society of Nuclear Medicine</publisher><subject>Adult ; Aged ; Amino acids ; Brain cancer ; Brain Neoplasms - diagnostic imaging ; Brain Neoplasms - therapy ; Chemoradiotherapy ; Contrast Media ; Disease Progression ; Disease-Free Survival ; Drug therapy ; Female ; Gadolinium ; Glioblastoma - diagnostic imaging ; Glioblastoma - therapy ; Humans ; Kaplan-Meier Estimate ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Neurosurgical Procedures ; Positron-Emission Tomography ; Prognosis ; Proportional Hazards Models ; Prospective Studies ; Radiation therapy ; Radiopharmaceuticals ; Studies ; Survival Analysis ; Treatment Outcome ; Tumors ; Tyrosine - analogs & derivatives</subject><ispartof>Journal of Nuclear Medicine, 2012-07, Vol.53 (7), p.1048-1057</ispartof><rights>Copyright Society of Nuclear Medicine Jul 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-38c9e8fcac5914b5cfd45170778d56e3f0549d3456c53e19160b9352465ee0543</citedby><cites>FETCH-LOGICAL-c372t-38c9e8fcac5914b5cfd45170778d56e3f0549d3456c53e19160b9352465ee0543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22645298$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Galldiks, Norbert</creatorcontrib><creatorcontrib>Langen, Karl-Josef</creatorcontrib><creatorcontrib>Holy, Richard</creatorcontrib><creatorcontrib>Pinkawa, Michael</creatorcontrib><creatorcontrib>Stoffels, Gabriele</creatorcontrib><creatorcontrib>Nolte, Kay W</creatorcontrib><creatorcontrib>Kaiser, Hans J</creatorcontrib><creatorcontrib>Filss, Christan P</creatorcontrib><creatorcontrib>Fink, Gereon R</creatorcontrib><creatorcontrib>Coenen, Heinz H</creatorcontrib><creatorcontrib>Eble, Michael J</creatorcontrib><creatorcontrib>Piroth, Marc D</creatorcontrib><title>Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression. In this study, we investigated the predictive value of PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET PET) during treatment.
In a prospective study, 25 patients with glioblastoma were investigated by MRI and (18)F-FET PET after surgery (MRI-/FET-1), early (7-10 d) after completion of radiochemotherapy with temozolomide (RCX) (MRI-/FET-2), and 6-8 wk later (MRI-/FET-3). Maximum and mean tumor-to-brain ratios (TBR(max) and TBR(mean), respectively) were determined by region-of-interest analyses. Furthermore, gadolinium contrast-enhancement volumes on MRI (Gd-volume) and tumor volumes in (18)F-FET PET images with a tumor-to-brain ratio greater than 1.6 (T(vol 1.6)) were calculated using threshold-based volume-of-interest analyses. The patients were grouped into responders and nonresponders according to the changes of these parameters at different cutoffs, and the influence on progression-free survival and overall survival was tested using univariate and multivariate survival analyses and by receiver-operating-characteristic analyses.
Early after completion of RCX, a decrease of both TBR(max) and TBR(mean) was a highly significant and independent statistical predictor for progression-free survival and overall survival. Receiver-operating-characteristic analysis showed that a decrease of the TBR(max) between FET-1 and FET-2 of more than 20% predicted favorable survival [corrected], with a sensitivity of 83% and a specificity of 67% (area under the curve, 0.75). Six to eight weeks later, the predictive value of TBR(max) and TBR(mean) was less significant, but an association between a decrease of T(vol 1.6) and PFS was noted. In contrast, Gd-volume changes had no significant predictive value for survival.
In contrast to Gd-volumes on MRI, changes in (18)F-FET PET may be a valuable parameter to assess treatment response in glioblastoma and to predict survival time.</description><subject>Adult</subject><subject>Aged</subject><subject>Amino acids</subject><subject>Brain cancer</subject><subject>Brain Neoplasms - diagnostic imaging</subject><subject>Brain Neoplasms - therapy</subject><subject>Chemoradiotherapy</subject><subject>Contrast Media</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Gadolinium</subject><subject>Glioblastoma - diagnostic imaging</subject><subject>Glioblastoma - therapy</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neurosurgical Procedures</subject><subject>Positron-Emission Tomography</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Prospective Studies</subject><subject>Radiation therapy</subject><subject>Radiopharmaceuticals</subject><subject>Studies</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Tyrosine - analogs & derivatives</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpdkU1r3DAQhkVpaDbb_oBeiqCX5KCtPixZOoaQpIEtCSU9G612nHixLVcjU_bS315tNrn0JEbzzIs0DyGfBV9JZ-pvu3EeYLsSQqy4s9rxd2QhtNJMG1O_JwsujGBac31KzhB3nHNjrf1ATqU0lZbOLsjfS0RAHGDMNLY0J_D5pUiAUxwRaDfSyeeu3CH90-Vn-tR3cdN7zHHwdMZufKL37FwyYW9Y288xRcjP-_6CrVnep1gAoA_Xj4egEIfJpw7jSHOkP37efSQnre8RPr2eS_Lr5vrx6jtb39_eXV2uWVC1zEzZ4MC2wQftRLXRod1WWtS8ru1WG1At15XbqkqboBUIJwzfOKVlZTRA6aklOT_mTin-ngFzM3QYoO_9CHHGRnCppJPGqIJ-_Q_dxTmN5XUHypXYuux4ScSRCuWHmKBtptQNPu0L1BzkNEc5TZHTHOWUmS-vyfPm0HqbeLOh_gHASIs0</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Galldiks, Norbert</creator><creator>Langen, Karl-Josef</creator><creator>Holy, Richard</creator><creator>Pinkawa, Michael</creator><creator>Stoffels, Gabriele</creator><creator>Nolte, Kay W</creator><creator>Kaiser, Hans J</creator><creator>Filss, Christan P</creator><creator>Fink, Gereon R</creator><creator>Coenen, Heinz H</creator><creator>Eble, Michael J</creator><creator>Piroth, Marc D</creator><general>Society of Nuclear Medicine</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>201207</creationdate><title>Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI</title><author>Galldiks, Norbert ; Langen, Karl-Josef ; Holy, Richard ; Pinkawa, Michael ; Stoffels, Gabriele ; Nolte, Kay W ; Kaiser, Hans J ; Filss, Christan P ; Fink, Gereon R ; Coenen, Heinz H ; Eble, Michael J ; Piroth, Marc D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-38c9e8fcac5914b5cfd45170778d56e3f0549d3456c53e19160b9352465ee0543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Amino acids</topic><topic>Brain cancer</topic><topic>Brain Neoplasms - diagnostic imaging</topic><topic>Brain Neoplasms - therapy</topic><topic>Chemoradiotherapy</topic><topic>Contrast Media</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Gadolinium</topic><topic>Glioblastoma - diagnostic imaging</topic><topic>Glioblastoma - therapy</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neurosurgical Procedures</topic><topic>Positron-Emission Tomography</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Prospective Studies</topic><topic>Radiation therapy</topic><topic>Radiopharmaceuticals</topic><topic>Studies</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Tyrosine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Galldiks, Norbert</creatorcontrib><creatorcontrib>Langen, Karl-Josef</creatorcontrib><creatorcontrib>Holy, Richard</creatorcontrib><creatorcontrib>Pinkawa, Michael</creatorcontrib><creatorcontrib>Stoffels, Gabriele</creatorcontrib><creatorcontrib>Nolte, Kay W</creatorcontrib><creatorcontrib>Kaiser, Hans J</creatorcontrib><creatorcontrib>Filss, Christan P</creatorcontrib><creatorcontrib>Fink, Gereon R</creatorcontrib><creatorcontrib>Coenen, Heinz H</creatorcontrib><creatorcontrib>Eble, Michael J</creatorcontrib><creatorcontrib>Piroth, Marc D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Galldiks, Norbert</au><au>Langen, Karl-Josef</au><au>Holy, Richard</au><au>Pinkawa, Michael</au><au>Stoffels, Gabriele</au><au>Nolte, Kay W</au><au>Kaiser, Hans J</au><au>Filss, Christan P</au><au>Fink, Gereon R</au><au>Coenen, Heinz H</au><au>Eble, Michael J</au><au>Piroth, Marc D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2012-07</date><risdate>2012</risdate><volume>53</volume><issue>7</issue><spage>1048</spage><epage>1057</epage><pages>1048-1057</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><coden>JNMEAQ</coden><abstract>The assessment of treatment response in glioblastoma is difficult with MRI because reactive blood-brain barrier alterations with contrast enhancement can mimic tumor progression. In this study, we investigated the predictive value of PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET PET) during treatment.
In a prospective study, 25 patients with glioblastoma were investigated by MRI and (18)F-FET PET after surgery (MRI-/FET-1), early (7-10 d) after completion of radiochemotherapy with temozolomide (RCX) (MRI-/FET-2), and 6-8 wk later (MRI-/FET-3). Maximum and mean tumor-to-brain ratios (TBR(max) and TBR(mean), respectively) were determined by region-of-interest analyses. Furthermore, gadolinium contrast-enhancement volumes on MRI (Gd-volume) and tumor volumes in (18)F-FET PET images with a tumor-to-brain ratio greater than 1.6 (T(vol 1.6)) were calculated using threshold-based volume-of-interest analyses. The patients were grouped into responders and nonresponders according to the changes of these parameters at different cutoffs, and the influence on progression-free survival and overall survival was tested using univariate and multivariate survival analyses and by receiver-operating-characteristic analyses.
Early after completion of RCX, a decrease of both TBR(max) and TBR(mean) was a highly significant and independent statistical predictor for progression-free survival and overall survival. Receiver-operating-characteristic analysis showed that a decrease of the TBR(max) between FET-1 and FET-2 of more than 20% predicted favorable survival [corrected], with a sensitivity of 83% and a specificity of 67% (area under the curve, 0.75). Six to eight weeks later, the predictive value of TBR(max) and TBR(mean) was less significant, but an association between a decrease of T(vol 1.6) and PFS was noted. In contrast, Gd-volume changes had no significant predictive value for survival.
In contrast to Gd-volumes on MRI, changes in (18)F-FET PET may be a valuable parameter to assess treatment response in glioblastoma and to predict survival time.</abstract><cop>United States</cop><pub>Society of Nuclear Medicine</pub><pmid>22645298</pmid><doi>10.2967/jnumed.111.098590</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | Journal of Nuclear Medicine, 2012-07, Vol.53 (7), p.1048-1057 |
| issn | 0161-5505 1535-5667 2159-662X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1023292663 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Amino acids Brain cancer Brain Neoplasms - diagnostic imaging Brain Neoplasms - therapy Chemoradiotherapy Contrast Media Disease Progression Disease-Free Survival Drug therapy Female Gadolinium Glioblastoma - diagnostic imaging Glioblastoma - therapy Humans Kaplan-Meier Estimate Magnetic Resonance Imaging Male Middle Aged Neurosurgical Procedures Positron-Emission Tomography Prognosis Proportional Hazards Models Prospective Studies Radiation therapy Radiopharmaceuticals Studies Survival Analysis Treatment Outcome Tumors Tyrosine - analogs & derivatives |
| title | Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T09%3A24%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessment%20of%20treatment%20response%20in%20patients%20with%20glioblastoma%20using%20O-(2-18F-fluoroethyl)-L-tyrosine%20PET%20in%20comparison%20to%20MRI&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Galldiks,%20Norbert&rft.date=2012-07&rft.volume=53&rft.issue=7&rft.spage=1048&rft.epage=1057&rft.pages=1048-1057&rft.issn=0161-5505&rft.eissn=1535-5667&rft.coden=JNMEAQ&rft_id=info:doi/10.2967/jnumed.111.098590&rft_dat=%3Cproquest_cross%3E2722873091%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1029935715&rft_id=info:pmid/22645298&rfr_iscdi=true |